Synthetic Biology Startups

SynsoryBio develops protein-based drugs that detect their location in the body and activate only at diseased tissue, with applications across cancer and autoimmune conditions.

2 investors

TareBio operates a platform for developing personalized and population-level vaccines against cancer and infectious diseases by analyzing immune cells already responding to a disease and reverse-engineering the antigens that activate them. The company works in the biotechnology and vaccine development space.

2 investors

ACX develops bioengineered solutions for pest control in agriculture, replacing synthetic chemicals with precision biocides. The company serves crop producers and aims to enhance food security while reducing chemical dependence and promoting biodiversity.

1 investor

Amino Analytica designs rapid molecular diagnostic tests for emerging infectious diseases and biological threats, developed in weeks rather than the traditional 12+ months. The company combines point-of-care diagnostics technology with AI-driven bionanotechnology to enable earlier detection and faster pandemic response.

1 investor

Cisterna Biologics develops yeast-engineered mRNA manufacturing technology that can be selectively purified to drive protein expression in human cells. The company targets cost-effective, scalable, and non-immunogenic mRNA production for therapeutic applications.

1 investor

Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

1 investor

Molagri develops biopesticides that target harmful insects through specific molecular mechanisms while protecting beneficial insects and the environment, and incorporates resistance modeling to maintain product efficacy over time.

1 investor

Pando develops enzyme design and optimization using machine learning to accelerate the design-build-test-learn cycle for biotechnology applications.

1 investor

Twenty Two develops AI-powered biosecurity infrastructure for screening and monitoring biological threats across the emerging bioeconomy. The platform provides automated customer screening, functional sequence prediction, and model safeguards to help organizations comply with dual-use research regulations.

1 investor